Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
IO KOLs Speak On WOLCHOK from 6/2017
https://www.lifescienceleader.com/doc/io-kols-speak-on-0001
CELL OUT, CELL IN
On the other end of the band from ablation and developing in parallel to off-the-shelf immuno-therapeutics is CAR-T (chimeric antigen receptor therapy), which involves removing T cells from a patient, training them to recognize the patient’s cancer, and reintroducing the engineered cells back into the body. Most of our KOL contributors remain optimistic that the logistical and business challenges of CAR-T will yield to solution and don’t necessarily see the procedure as a competitive alternative to off-the-shelf approaches.
“Perhaps there is a role for manipulating immune checkpoints at the same time as you’re redirecting T cells toward targets of interest on the tumor,” says Wolchok, whose group is also working with CAR-T. “We are seeing these different approaches come together — the science is driving the field forward in a very strong way, and thankfully there are considerable technical advances as well. Dr. Carl June’s group at the University of Pennsylvania is applying new knowledge of inhibitory and agonist pathways to enhance the activity of the CAR-T cells. Such developments have allowed our group to do sophisticated manipulation of CAR-T cells under the leadership of Dr. Michelle Settling.”
Wolchok believes the CAR-T model will thrive in the same type of research-treatment settings that have fostered blood stem-cell transplants. “Again, advances in the technology of cell expansion are coming along well, allowing for more widespread application.”
CROSS-CULTURAL COLLABORATORS
Wolchok - Phosphatidylserine targeting antibody in combination with tumor radiation and immune checkpoint blockade promotes anti-tumor activity in mouse B16 melanoma
Ludwig Presence at 2017 Society for Immunotherapy of Cancer (SITC)
Annual Meeting
http://www.ludwigcancerresearch.org/sites/default/files/media/ckeditor/380/Ludwig%20Presence%20at%202017%20Society%20for%20Immunotherapy%20of%20Cancer.pdf
Principles of cancer immunotherapy - Wolchok
https://www.uptodate.com/contents/principles-of-cancer-immunotherapy#H28828736
Roche win boosts case for adding chemo to cancer immunotherapy - RTRS
20-Nov-2017 15:20
Win tilts competitive landscape in big lung cancer market
Roche, Merck & Co main backers of chemo-combo therapy
AstraZeneca, Bristol-Myers betting on dual immunotherapies
By Ben Hirschler
LONDON, Nov 20 (Reuters) - Cancer doctors struggling to work out the best way to use modern immunotherapy drugs now have further evidence of the benefits of adding them to chemotherapy, despite earlier scepticism.
News that Roche's ROG.S immune system-boosting drug Tecentriq delayed lung cancer progression when given alongside chemo and its older drug Avastin validates the approach for the first time in a large Phase III clinical trial. (Full Story)
It is a significant milestone for physicians, patients and investors, who are trying to assess the competitive landscape as drugmakers race to develop better ways to fight tumours in previously untreated lung cancer.
Lung cancer is by far the biggest oncology market and first-line treatment provides access to the most patients, opening up potential annual sales forecast by some analysts at $20 billion.
Roche and Merck & Co MRK.N have led the way in pioneering so-called "chemo-combo" treatment, while AstraZeneca AZN.L and Bristol-Myers BMY.N are betting primarily on mixing two immunotherapies. AstraZeneca notably failed to show a similar benefit in a high-profile clinical trial in July. (Full Story)
Stefan Zimmermann, an oncologist at Lausanne University Hospital in Switzerland, said the Roche data would help scotch concerns that chemo might hamper the new class of immuno-oncology medicines.
"Many experts in the field will be relieved because there has been uncertainty ... I think this will really encourage many of us to use this combination upfront," he told Reuters.
"For now, the only positive data that we have is for chemo combination."
Merck, in fact, already has U.S. approval to add chemo to its immunotherapy drug Keytruda - but this was based on a small trial and the company withdrew a similar European application last month, knocking confidence in its strategy. (Full Story)
Since Keytruda, Bristol's Opdivo, Roche's Tecentriq and AstraZeneca's Imfinzi are all rival inhibitors of biological switches known as PD-1 or PD-L1, the market is "largely a zero-sum game", according to Bernstein analyst Tim Anderson.
"Roche's good fortune means there is less to go around for other companies," he said.
In the case of Merck, the U.S. drugmaker now faces a rival with a different and perhaps superior drug combination. Roche believes adding Avastin in addition to chemo can further help restore anti-cancer immunity.
For AstraZeneca and Bristol, the bar has just been raised for two other key clinical trials sponsored by the drugmakers that are expected to report results in 2018.
Roche itself will present full results on the ability of its new combination to delay the worsening of lung cancer at a European Society for Medical Oncology meeting in Geneva on Dec. 7. Data on whether it also helps patients live longer is expected in the first half of next year.
Overall survival is the gold standard in cancer care but proving a treatment extends the time before disease progresses is an important marker on the way.
"If there is positive progression-free survival then I think it is very, very likely this will also translate into an overall survival benefit over time," said Zimmermann.
Bioinspired Cell-Derived Nanovesicles versus Exosomes as Drug Delivery Systems: a Cost-Effective Alternative
Yes. And they are just after Avid. LOL
Hypoxia-/HIF-driven Generation of Adenosine and Lactate, Acidosis, Expression of VEGF/VEGFR and Externalization of Phosphatidylserine: A Fatal Quintet of the Tumor Microenvironment Impeding Anti-tumor Immune Response and
Promoting Malignant Progression P. Vaupel
THE TUMOR MICROENVIRONMENT
15th International Workshop
Saturday April 29, 2017
Session VI: Cancer Therapeutics and Immuno-Oncology
https://www.google.at/url?sa=t&source=web&rct=j&url=http://www.tmworkshop.org/uploads/3/4/4/9/34490728/web_page_agenda%5B1472%5D.pdf&ved=0ahUKEwik7tao38jXAhWBWRoKHa9rCSI4jAEQFggnMAE&usg=AOvVaw3-1n57ZmBeHXGNPByR7MNP
Phosphatidylserine- targeted nanotherapy in cancer: A journey from discovery research to clinical trials
Xiaoyang Qi, University of Cincinnati College of Medicine, USA
Oncology and
Cancer Therapeutics
October 30- November 01, 2017 | Chicago, USA
https://www.google.at/url?sa=t&source=web&rct=j&url=http://alliedacademies.com/oncology-and-therapeutics/2017/final-program.pdf&ved=0ahUKEwjh897c3MjXAhXDbBoKHSSECCU4eBAWCDwwBw&usg=AOvVaw0ANCuSSRngFfQoWuUcT3_u
3521 Pathophysiologic Implications of Type-2 Phosphatidylserine-Positive Erythrocytes in Hemoglobin SS Disease (sickle cell anemia) and ß-Thalassemia
https://ash.confex.com/ash/2017/webprogram/Paper105340.html
2376 Phosphatidylserine on Blood Cells and Microparticles Contributes to the Hyper-Coagulable State in Diabetic Kidney Disease
https://ash.confex.com/ash/2017/webprogram/Paper104754.html
CJ how old is that article?
Protective Effect of Anti-Phosphatidylserine Antibody in a Guinea Pig Model of Advanced Hemorrhagic Arenavirus Infection
https://benthamopen.com/EPUB/BSP-TOMICROJ-2017-76
And Dart is part of this game?
RB Birge
Requirement of Gamma-Carboxyglutamic Acid Modification and Phosphatidylserine Binding for the Activation of Tyro3, Axl, and Mertk Receptors by Growth Arrest-Specific 6
11.10.2017
https://www.frontiersin.org/articles/10.3389/fimmu.2017.01521/full
A comprehensive overview of exosomes in ovarian cancer: emerging biomarkers and therapeutic strategies
https://ovarianresearch.biomedcentral.com/articles/10.1186/s13048-017-0368-6
Exosomes in Toxicology: Relevance to Chemical Exposure and Pathogenesis of Environmentally Linked Diseases
Exosome Surface Markers May Enable Cancer-Specific Dx Tests
Mar 07, 2017 !!! not brand new
https://www.genomeweb.com/molecular-diagnostics/exosome-surface-markers-may-enable-cancer-specific-dx-tests
Lipid Summary Phosphatidylserine
http://exocarta.org/lipid_summary?lipid_id=Phosphatidylserine%20(PS)&species=Homo%20sapiens
Verified November 2017 by Novartis ( Novartis Pharmaceuticals )
They have PS on the table!
Study of PDR001 and/or MBG453 in Combination With Decitabine in Patients With AML or High Risk MDS
Drug: MBG453
MBG453 is a high-affinity, humanized anti-TIM-3 IgG4 monoclonal antibody which blocks the binding of TIM-3 to phosphatidylserine (PtdSer).
https://clinicaltrials.gov/ct2/show/NCT03066648
The Effect of L-Amino Acid Oxidase on Hep-2 Squamous Cell Carcinoma Cell Line
Published: November 07 2017
http://medcraveonline.com/MOJCRR/MOJCRR-01-00001.pdf
Wclc 2017
https://www.carenet.com/news/general/carenet/45002
Translation
Anti-PS antibody bavituximab enhances activity of immunity checkpoint inhibitors: Results of SUNRISE study subgroup / WCLC 2017
2017/11/15
Care net
Phosphatidylserin (PS) is widely expressed on the surface of cells in the cancer microenvironment, suppresses induction of tumor-specific T cells, and expresses high immunosuppressive effect. bavituximab is a mela IgG1 monoclonal antibody targeting PS, tumor ... [ read more ]
(Care Net Hosoda Masayuki)
How this R&D company is transitioning to a pure-play CDMO: ‘Opportunities are almost endless’
https://www.outsourcing-pharma.com/Article/2017/11/15/Peregrine-transitioning-to-pure-play-CDMO?utm_source=copyright&utm_medium=OnSite&utm_campaign=copyright
Kennedy Capital Management, Inc. 0,15% 69.820,00 -1.324.246,00 219.234,80 30-09-2017
PPHM Investors (not all!)
Investor Name % Outstanding Position Position Change Value ($) Filing Date
Ronin Trading, L.L.C. 9,25% 4.173.392,00 +372.253,00 19.155.869,28 26-10-2017
Tappan Street Partners LLC 8,49% 3.829.504,00 +1.597.927,00 17.041.292,80 06-11-2017
Eastern Capital, Ltd. 8,38% 3.777.183,00 +3.777.183,00 11.709.267,30 25-08-2017
The Vanguard Group, Inc. 2,28% 1.029.734,00 +146.788,00 4.382.547,90 30-06-2017
BlackRock Institutional Trust Company, N.A. 1,67% 755.003,00 -37.781,00 3.213.292,77 30-06-2017
Bandera Partners LLC 1,23% 555.000,00 +352.000,00 1.742.700,00 30-09-2017
Renaissance Technologies LLC 1,21% 547.190,00 +66.040,00 1.718.176,60 30-09-2017
Geode Capital Management, L.L.C. 0,50% 225.675,00 +20.319,00 960.472,80 30-06-2017
Stifel Nicolaus Investment Advisors 0,45% 204.305,00 +200.762,00 641.517,70 30-09-2017
Eqis Capital Management, Inc. 0,32% 143.595,00 -6.801,00 450.888,30 30-09-2017
Wells Fargo Advisors 0,23% 104.202,00 +55.862,00 327.194,28 30-09-2017
Swartz (Eric S) 0,21% 96.017,00 0 297.652,70 25-08-2017
Phatak (Prasad) 0,19% 86.107,00 +19.000,00 383.176,15 06-11-2017
Brown Advisory Securities, LLC 0,18% 82.858,00 +1,00 260.174,12 30-09-2017
Jacobs Levy Equity Management, Inc. 0,18% 82.414,00 -2.329,00 350.753,98 30-06-2017
AXA Rosenberg Investment Management LLC 0,18% 81.700,00 +81.700,00 256.538,00 30-09-2017
Northern Trust Investments, Inc. 0,17% 77.192,00 +12.947,00 242.382,88 30-09-2017
OxFORD Asset Management 0,16% 73.517,00 +73.517,00 230.843,38 30-09-2017
J.P. Morgan Securities LLC 0,16% 72.069,00 +67.783,00 226.296,66 30-09-2017
QS Investors, LLC 0,16% 71.914,00 0 306.065,98 30-06-2017
Kennedy Capital Management, Inc. 0,15% 69.820,00 -1.324.246,00 219.234,80 30-09-2017
California Public Employees' Retirement System 0,15% 68.543,00 0 291.719,01 30-06-2017
Commonwealth Financial Network 0,13% 57.919,00 -2.832,00 181.865,66 30-09-2017
BlackRock Financial Management, Inc. 0,11% 51.003,00 -11.650,00 217.068,77 30-06-2017
Bamforth Mark R 0,11% 50.000,00 +50.000,00 229.500,00 27-10-2017
Riedweg & Hrovat AG 0,09% 41.428,00 +20.714,00 176.069,00 31-07-2017
King (Steven W) 0,07% 33.248,00 +1,00 103.068,80 25-08-2017
Citadel LLC 0,07% 32.998,00 -18.009,00 103.613,72 30-09-2017
BNY Mellon Asset Management 0,06% 27.569,00 0 117.333,66 30-06-2017
AQR Capital Management, LLC 0,06% 27.284,00 0 116.120,70 30-06-2017
CP yes.
But till now we SH have nothing except losses (except Ronin).
Peregrine Announces Date of 2017 Annual Meeting of Stockholders - GNW
13-Nov-2017 14:05
TUSTIN, Calif., Nov. 13, 2017 (GLOBE NEWSWIRE) -- Peregrine Pharmaceuticals, Inc. (NASDAQ:PPHM) (NASDAQ:PPHMP) today announced that its 2017 Annual Meeting of Stockholders will be held on January 18, 2018, at 14191 Myford Road, Tustin, California 92780, located within the company’s manufacturing campus. Holders of the company’s common stock at the close of business on November 27, 2017, the record date, will be entitled to receive notice of and vote their shares at the 2017 Annual Meeting.
About Peregrine Pharmaceuticals, Inc. Peregrine Pharmaceuticals, Inc. is a company transitioning from an R&D focused business to a pure play contract development and manufacturing organization (CDMO). Peregrine's in-house CDMO services, including cGMP manufacturing and development capabilities, are provided through its wholly-owned subsidiary Avid Bioservices, Inc. (www.avidbio.com).
The company is pursuing to license or sell its proprietary R&D assets, including its lead immunotherapy candidate, bavituximab, which is currently being evaluated in clinical trials in combination with immune stimulating therapies for the treatment of various cancers. For more information, please visit www.peregrineinc.com.
About Avid Bioservices, Inc.
Avid Bioservices, Inc., a wholly owned subsidiary of Peregrine Pharmaceuticals, provides a comprehensive range of process development, high quality cGMP clinical and commercial manufacturing services for the biotechnology and biopharmaceutical industries. With over 20 years of experience producing monoclonal antibodies and recombinant proteins in batch, fed-batch and perfusion modes, Avid's services include cGMP clinical and commercial product manufacturing, purification, bulk packaging, stability testing and regulatory strategy, submission and support. The company also provides a variety of process development activities, including cell line development and optimization, cell culture and feed optimization, analytical methods development and product characterization. For more information about Avid, please visit www.avidbio.com.
Important Additional Information Peregrine intends to file a proxy statement with the Securities and Exchange Commission (SEC) in connection with the solicitation of proxies for Peregrine's 2017 Annual Meeting (Proxy Statement) with an associated WHITE proxy card. Peregrine, its directors and certain of its executive officers will be participants in the solicitation of proxies from stockholders in respect of the 2017 Annual Meeting. Information regarding the names of Peregrine's directors and executive officers and their respective interests in Peregrine by security holdings or otherwise is set forth in the Annual Report on Form 10-K of Peregrine, for the fiscal year ended April 30, 2017, filed with the SEC on July 14, 2017, as amended by Amendment No. 1 on Form 10-K/A filed with the SEC on August 28, 2017, and Peregrine's proxy statement for the 2016 Annual Meeting, filed with the SEC on August 26, 2016. To the extent holdings of such participants in Peregrine's securities are not reported, or have changed since the amounts described, in the Form 10-K/A, such changes have been reflected on Initial Statements of Beneficial Ownership on Form 3 or Statements of Change in Ownership on Form 4 filed with the SEC. Details concerning the nominees of Peregrine's Board of Directors for election at the 2017 Annual Meeting will be included in the Proxy Statement. BEFORE MAKING ANY VOTING DECISION, INVESTORS AND STOCKHOLDERS OF THE COMPANY ARE URGED TO READ ALL RELEVANT DOCUMENTS FILED WITH OR FURNISHED TO THE SEC, INCLUDING THE COMPANY'S DEFINITIVE PROXY STATEMENT AND ANY SUPPLEMENTS THERETO, BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION. Investors and stockholders will be able to obtain a copy of the definitive proxy statement and other documents filed by Peregrine free of charge from the SEC's website, www.sec.gov. Peregrine's stockholders will also be able to obtain, without charge, a copy of the definitive Proxy Statement and other relevant filed documents by directing a request by mail to Peregrine, Corporate Secretary's Office, 14282 Franklin Avenue, Tustin, CA 92780, by calling Peregrine's proxy solicitor, MacKenzie Partners, Inc., toll-free at (800) 322-2885, or from Peregrine's website at www.Peregrine.com.
Media Contacts
John Christiansen / Matt Reid
Sard Verbinnen & Co
(415) 618-8750 / (310) 201-2040
Investor Contacts
Stephanie Diaz
Vida Strategic Partners
(415) 675-7401
GlobeNewswire, Inc. 2017
A novel therapeutic strategy for cancer using phosphatidylserine targeting stearylamine-bearing cationic liposomes
Available online 1 November 2017
1364P Final clinical results from SUNRISE: A phase III, randomized, double-blind, placebo-controlled multicenter trial of bavituximab plus docetaxel in patients with previously treated stage IIIb/IV nonsquamous non-small cell lung cancer
Published: 18 September 2017
Pls delete if already posted.
https://academic.oup.com/annonc/article/28/suppl_5/mdx380.065/4109420
I can't find any source for your statement.
Is it insider-info? Or pure wish and fantasy?? Just wanna doublecheck - cause there are a lot of misleading information out there.
I am just amused about the coloured cards - that's all.
Oh.... there is no link to proof that source
There is NO source.
Board members talking about a white, red or blue card.
Soon we will have the whole colours of the rainbow.
From this board.
So we (will) have a
White card
Red card
Blue card
Have I missed one?
That's it.
Wook you have my vote.
Ahhhhh
You answer a question with a question.
Head And Neck Cancer – Pharmaceutical & Healthcare disease Pipeline Review, H2 2017
NOVEMBER 2ND, 2017
Companies Mentioned in the Report
Peregrine Pharmaceuticals Inc. - and some others
https://www.medgadget.com/2017/11/head-and-neck-cancer-pharmaceutical-healthcare-disease-pipeline-review-h2-2017.html
Modified Annexin A5 (AnxA5MOD)Immunotherapy Delivery Platform
Phosphatidylserine
http://www.rubiconbio.com/download/Modified%20Annexin%20Update%20for%20Website%20FINAL.pdf?bcsi_scan_1014b4c4c7c5e188=0&bcsi_scan_filename=Modified%20Annexin%20Update%20for%20Website%20FINAL.pdf
P2.02 - Biology/Pathology (ID 616) S. Antonia
Event: WCLC 2017Type: Poster Session with Presenters PresentTrack: Biology/PathologyPresentations: 1
Moderators:Coordinates: 10/17/2017, 09:30 - 16:00, Exhibit Hall (Hall B + C)
-
P2.02-030 - Bavituximab in Combination With Nivolumab Enhances Tumor Immune Response in a 3D Ex Vivo System of Lung Cancer Patients (ID 8683)
09:30 - 09:30 | Author(s): S. Antonia
Abstract
Background:
Bavituximab is a chimeric monoclonal antibody that targets the membrane phospholipid phosphatidylserine (PS) exposed on endothelial cells and cancer cells in solid tumors. Our previous studies showed that bavituximab enhances the activation of CD8+ TILs that correlates with increased cytokine production by lymphoid and myeloid cells in lung cancer with low PD-L1 expression suggesting that the interruption of the PD-1/PD-L1 axis by nivolumab may enhance the bavituximab effect in tumors.
Method:
Fresh tumor tissues obtained from consented patients with NSCLC, urothelial carcinoma or renal cell carcinoma at the time of surgical resection were utilized in a proprietary 3D ex vivo tumor miscrosphere assay, where 3D tumor microspheres were treated with bavituximab or nivolumab alone or in combination at 10 mg/ml for 36 hours. At the end of the treatment, a multiplex human cytokine assay was used to simultaneously analyze the differential secretion of cytokines, including human IFNg, in culture media as a surrogate of TIL activation. In addition, gene expression analysis of microspheres was performed using the NanoString PanCancer Immune Profiling panel which contains probes to quantitate 770 immune function genes.
Result:
Preliminary results indicate the combination treatment with bavituximab and nivolumab led to increased expression of genes involved in M1 polarization of tumor associated macrophages in a subpopulation of lung tumors that closely correlated with release of cytokines such as MIP1b (CCL4) which is a chemoattractant for natural killer cells, monocytes and a variety of other cells involved in tumor immune response.
Conclusion:
This lung patient derived ex-vivo approach indicates that bavituximab in combination with nivolumab may enhance immune response. This response likely involves M1 polarization of tumor associated macrophages and suggests potential clinical implications in the treatment of lung cancer.
https://library.iaslc.org/search-speaker?search_speaker=53549
A novel protein derived from lamprey supraneural body tissue with efficient cytocidal actions against tumor cells
https://biosignaling.biomedcentral.com/articles/10.1186/s12964-017-0198-6